TABLE 2.

TGF-β superfamily in MASLD/MASH.

S.N.	Title	Type of article	References
1	Inevitable role of TGF-β1 in progression of nonalcoholic fatty liver disease	Review	Nair and Nath (2020)
2	TGF-β signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism	Research paper	Yang et al. (2014)
3	Smad3 phospho-isoform signaling in nonalcoholic steatohepatitis	Review	Yamaguchi et al. (2022)
4	Roles of transforming growth factor-β signaling in liver disease	Review	Wang, X. L. et al. (2024)
5	TGF-β in progression of liver disease	Review	Dooley and ten Dijke (2012)
6	The rationale for targeting TGF-β in chronic liver diseases	Review	Giannelli et al. (2016b)
7	Assessing the combined impact of fatty liver-induced TGF-β1 and LPS-activated macrophages in fibrosis through a novel 3D serial section methodology	Research paper	Ishiyama et al. (2024)
8	ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway	Research paper	Liu et al. (2023b)
9	TGF-β1 and TGF-β2 abundance in liver diseases of mice and men	Research paper	Dropmann et al. (2016)
10	TGF-β and HIPPO signaling pathways interplay in distinct hepatic contexts	Review	Color-Aparicio et al. (2024)
11	The activin axis in liver biology and disease	Review	Rodgarkia-Dara et al. (2006)
12	A complex role of activin A in non-alcoholic fatty liver disease	Research paper	Yndestad et al. (2009)
13	Gastrointestinal pharmacology activins in liver health and disease	Review	Hamang et al. (2023)
14	Roles of activin A and Gpnmb in metabolic dysfunction-associated steatotic liver disease (MASLD)	Research paper	Liu, H. et al. (2023b)
15	Unveiling the impact of BMP9 in liver diseases: Insights into pathogenesis and therapeutic potential	Review	Chen et al. (2024)
16	Circulating bone morphogenetic protein 9 (BMP9) as a new biomarker for noninvasive stratification of nonalcoholic fatty liver disease and metabolic syndrome	Research paper	Yang et al. (2024)
17	The role of bone morphogenetic protein 9 in nonalcoholic fatty liver disease in mice	Research paper	Sun et al. (2021)
18	Adenovirus-mediated overexpression of bone morphogenetic protein-9 promotes methionine choline deficiency-induced non-alcoholic steatohepatitis in non-obese mice	Research paper	Li et al. (2019)
19	Bone morphogenetic protein 4 alleviates nonalcoholic steatohepatitis by inhibiting hepatic ferroptosis	Research paper	Wang et al. (2022)
20	Growth differentiation factor 15 (GDF15) is associated with non-alcoholic fatty liver disease (NAFLD) in youth with overweight or obesity	Research paper	Galuppo et al. (2022)
21	Growth differentiation factor 15: Emerging role in liver diseases	Review	Li et al. (2024)
22	Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction	Research paper	Takeuchi et al. (2024)
23	Elevated serum growth differentiation factor 15 and decorin predict the fibrotic progression of metabolic dysfunction-associated steatotic liver disease	Research paper	Chang et al. (2024)
24	Expression and function of BMP and activin membrane-bound inhibitor (BAMBI) in chronic liver diseases and hepatocellular carcinoma	Review	Weber et al. (2023)
25	Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progression	Research paper	Bai et al. (2024)
26	TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop	Review	Ahmed et al. (2022)
27	Pathogenesis of non-alcoholic fatty liver disease mediated by YAP.	Research paper	Chen, P. et al. (2018)
28	TNFAIP3 interacting protein 3 overexpression suppresses nonalcoholic steatohepatitis by blocking TAK1 activation	Research paper	Liu et al. (2020)
29	Promotion of liver regeneration and anti-fibrotic effects of the TGF-β receptor kinase inhibitor galunisertib in CCl4-treated mice	Research paper	Masuda et al. (2020)